What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

1. Lysine Methyltransferase SMYD1 Regulates Myogenesis via skNAC Methylation.Cells · 2023
   Article
2. The SMYD1 and skNAC transcription factors contribute to neurodegenerative diseases.Brain, behavior, & immunity - health · 2020
   Article
3. Loss of SMYD1 Results in Perinatal Lethality via Selective Defects within Myotonic Muscle Descendants.Diseases (Basel, Switzerland) · 2018
   Article
4. SYT7 acts as a driver of hepatic metastasis formation of gastric cancer cells.Oncogene · 2018
   Article
5. Nanostructured Ti surfaces and retinoic acid/dexamethasone present a spatial framework for the maturation and amelogenesis of LS-8 cells.International journal of nanomedicine · 2018
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors at 1 institution in 1 country.

Funding

Abstract

Indexed as